Management of HAE

Management of HAE can be divided into various approaches. The aim of treatment of acute attacks, also referred to as ‘on demand therapy’ is to minimize their severity, including potentially fatal upper airway edema, and associated impairment of Quality of Life (QoL). Short term prophylaxis (STP) refers to treatment meant to minimize the risk of attacks when avoidance of potential and known triggers is not possible. Long term prophylaxis (LTP) refers to ongoing treatment of HAE aimed at minimizing the overall number, frequency and/or severity of attacks. The details of specific therapies for these treatment approaches are reviewed in the current Canadian Hereditary Angioedema Guidelines.


Health Canada Approved HAE Treatments

Health Canada has approved seven treatments for preventing and treating HAE attacks.

The information on this page is for educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please discuss all medical and treatment advice with your HAE specialist.

Acute Treatments

Acute attacks of HAE are unpredictable, disabling and can be life-threatening if the airway is affected. Quickly and effectively treating these attacks with acute treatments (also known as on-demand treatments) prevents complications and minimizes interference with everyday activities.

BERINERT® (C1-Esterase Inhibitor) - CSL Behring

FIRAZYR® (icatibant injection) - Takeda

Prophylaxis Treatments

Prophylactic treatment is medication taken on a regular schedule to reduce the frequency and/or severity of HAE attacks. This can be done on a long-term or short-term basis. Long-term prophylaxis is typically given regularly for weeks, months, or years in an effort to minimize the overall attack burden. Short-term prophylaxis is typically given just prior to a surgical or dental procedure to prevent an HAE attack during or following the procedure or during other times when patients may be more likely to have attacks. People with HAE receiving prophylactic treatment still need an effective on-demand treatment plan in the event the prophylactic treatment is not 100% effective.

CINRYZE® (C1 inhibitor) - Takeda
approved but not available on Canadian Blood Services formulary

HAEGARDA® (C1-Esterase Inhibitor Subcutaneous) CSL Behring

ORLADEYO™ (Berotralstat capsule) BioCryst

TAKHZYRO™ (lanadelumab injection) Takeda

Tranexamic acid is an anti-fibrinolytic agent taken orally. Further details can be found in the CHAEN HAE Guidelines.

Funding for Canadian Hereditary Angioedema Network has been generously provided by unrestricted grants from:


CSL Behring


Contact Us

20 Carlton Street, Suite 123
Toronto, ON M5B 2H5
Tel: 416-585-3000

Patient Images

Patient Images

Copyright © 2024 CHAEN-RCAOH

All rights reserved.

Privacy Policy

Powered by Wild Apricot Membership Software